DSpace Repository

Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?

Show simple item record

dc.contributor.author Porta, S.V.
dc.contributor.author Ugarte Gil, Manuel Francisco
dc.contributor.author Garciá-De La Torre, I.
dc.contributor.author Bonfá, E.
dc.contributor.author Gómez-Puerta, J.A.
dc.contributor.author Arnaud, L.
dc.contributor.author Cardiel, M.H.
dc.contributor.author Alarcón, Graciela S.
dc.contributor.author Pons-Estel, B.A.
dc.contributor.author Pons-Estel, G.
dc.date.accessioned 2022-06-01T13:53:58Z
dc.date.available 2022-06-01T13:53:58Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/11749
dc.description.abstract Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020. en_US
dc.language.iso eng
dc.publisher Wolters Kluwer Health
dc.relation.ispartofseries Journal of Clinical Rheumatology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Cyclophosphamide en_US
dc.subject glucocorticoids en_US
dc.subject incomplete lupus en_US
dc.subject Lupus nephritis en_US
dc.subject Mycophenolate en_US
dc.subject Systemic lupus erythematosus en_US
dc.subject Treatment en_US
dc.title Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately? en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1097/RHU.0000000000001803
dc.relation.issn 1536-7355


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics